Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein

OBJECTIVE: Participants in the Atherosclerosis Prevention in Paediatric Lupus Erythematosus (APPLE) trial were randomised to placebo or atorvastatin for 36 months. The primary endpoint, reduced carotid intima medial thickness (CIMT) progression, was not met but atorvastatin-treated participants show...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ardoin, Stacy P, Schanberg, Laura Eve, Sandborg, Christy I, Barnhart, Huiman X, Evans, Greg W, Yow, Eric, Mieszkalski, Kelly L, Ilowite, Norman T, Eberhard, Anne, Imundo, Lisa F, Kimura, Yuki, Levy, Deborah, von Scheven, Emily, Silverman, Earl, Bowyer, Suzanne L, Punaro, L, Singer, Nora G, Sherry, David D, McCurdy, Deborah K, Klein-Gitelman, Marissa, Wallace, Carol, Silver, Richard M, Wagner-Weiner, Linda, Higgins, Gloria C, Brunner, Hermine I, Jung, Lawrence, Soep, Jennifer B, Reed, Ann M, Thompson, Susan D
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4104199/
https://ncbi.nlm.nih.gov/pubmed/23436914
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2012-202315
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars